Combined Inhaled Short-Acting Beta2 Agonist and Anticholinergic Agents for Asthma.

Although the quality of evidence included in this review was low to moderate, the potential benefits of decreased hospitalization and relapse rates and the comparatively mild and limited adverse events suggest that patients presenting with acute asthma exacerbations are likely to benefit from combined short-acting anticholinergic and short-acting beta2 agonist.